Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight. The FDA has ...
Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a treatment for relapsed and refractory multiple myeloma (RRMM). The drugmaker ...
Zacks.com on MSN1mon
Sanofi's Sarclisa Gets FDA Nod for Expanded Use in Multiple MyelomaSanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa ...
Hosted on MSN11mon
Sanofi multiple myeloma drug shows potential in newly diagnosed casesSanofi (NASDAQ:SNY) said on Thursday its multiple myeloma drug Sarclisa (isatuximab) met the primary endpoints of a late-stage trial. The drug is currently indicated for use in a combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback